



QBD, REVIEW ON COMPREHENSIVE UNDERSTANDING OF BUILDING AN ANALYTICAL QUALITY BY DESIGN FOR DRUG MANUFACTURING PROCESS

Shishir Kumar Prasad, Dr. Kalpana Diwekar, Anita.A

Department of Pharmaceutical Chemistry, Dayananda Sagar University, Bangalore - 560078

Article Info: Received 26 March 2020; Accepted 13 April 2020

DOI: <https://doi.org/10.32553/jbpr.v9i2.744>

Corresponding author: Shishir Kumar Prasad

Conflict of interest statement: No conflict of interest

ABSTRACT

When knowledge based on pure scientific understanding and quality risk management is applied to product and process learning with regulation on process control along with a systematic approach for development of predefined objectives in analytical field then it is called as quality by design or QBD it follow ICH guidelines for quality in pharmaceutical product concept of qbd also extends to analytical methods, it is mandatory process in QBD to define a goal.

A protocol for the method which will continue monitoring the process throughout in a systematic way and working on alternate methods as well to get optimal performance, the methods given are carefully analysed in structured pattern for risks and is put for a challenge of the validity of method which later on can be taken for the criteria, benefit of these studies.

The performances can be improved as well as clearly understood along with the risk management and desired performance methods which can also be validated later on, the review briefly gives an inside view of application of analytical QBD in industries and its current status with examples and principles of analytical methods in HPTLC ,titration for moisture content, determination of toxic impurities in mixtures,quantative colour measurement and various spectroscopic method for identification of chemical moiety.

Qbd developed spectroscopic and chromatographic method are usually done as per ICH Q8 R2 , the critical parameters are compared to principle observation and analysis, the HPTLC method employs solvent usage and detection of absorbance and wavelength comparison.

Introduction

As science is now based on quality management system, with quality to be built in QBD aims into looking into the quality of analytical process during development stage itself instead of waiting for final result for an integrated approach to development manufacturing and quality for both industry and regulators. As per FDA guidelines for process validation at three step approach can be utilized

Stage 1: Design of atp {analytical target profile} the method and conditions required to control critical values

Stage 2: Qualification: the methods utilized is capable of its purpose

Stage 3: Continuous monitoring: the methods utilized are ensured to remain in monitoring for intended work

1) The new widely accepted protocol for QBD include a systematic approach like ↓↓



VARIOUS ELEMENTS OF QBD

1) Product and process design and development, The products are identified as per critical quality assessments and it is up fronted for the desired performance 2) The design formulation and process are made to meet the product specific requirement 3) Risk assessment and risk control it includes the impact of material testing to be clearly understood, product eqas and process parameter with various attributes are explained well 4) The identification and control of

variability in process and material management is followed, To assure the consistent quality all the process are continuously monitored and updated.

2) SYSTEM COMPARISON OF PHARMACUETICAL SUPPLY AND ANALYTICAL SYSTEM



TRADITIONAL APPROACH	QBD
PRODUCT DEVELOPMENT	PRODUCT DEVELOPMENT
FIXED BATCH MANUFACTURING	RESPONSIVE BATCH OR
PROCESS	CONTINUOUS
FIXED BATCH PACKAGIG PROCESS	MANUFACTURING PROCESS
PRODUCT QUARINTINE	REPONSIVE PKG PROCESS
PRODUCT DISRTIBUTION	PRODUCT DISTRIBUTION
FIXED PARAMETERS RANGES	DESIGN- CONTROL DTRATEGY
IN-PROCESS TESTING PROCESS	REAL TIME RELEASE
DOCUMENTATION	

3) QUALITY TARGET PRODUCT PROFILE: The perfect quality of a drug is ensured by all the acceptable control strategy and all the process with and formulation which are quite robust of the results. Critical quality attributes: A CQA is a characteristics that should be within an appropriate limit, range or distribution which can have physical, chemical biological or microbial property range or distribution to ensure the desire product quality as per the guidelines (ICH q 8 R2) CQAs which are generally associated with drug substance, intermediates, in processes, final products and excipients as well.


4) QUALITY RISK MANAGERMENTS: Q9 Describes systematic approach for assessment control communication review, it even applies for product lifecycle development manufacturing and distributions, it is also inclusive of principle methodologies and examples of tools for risk quality management and assessment of risk to quality should be linked to protection of patients based on scientific knowledge, and extend over the life cycle of the a pharmaceutical product.


5) PROCESS PARAMETERS: A process parameters whose viability has an impact on a critical quality attribute and therefore should be monitored or controlled to ensure the process the desired quality (q8 r2),cppc have a direct impact on CQAs,The examples in temperature ,ph, agitation, dissolved ratte of oxygen are all measured parameters which can be easily adjusted which are controlled as well are measured parameters.

6) QUALITY ATTRIBUTE DEEMED CRITICAL: A severity scale is used to assess relative magnitude of impact. A change is critical only when it is in severity



7) DESIGN SPACE APPROACH : First principle approach is combination of experimental data and mechanical knowledge of chemistry physics and engineering to model and predict performance, next is **non mechanistic or empirical approach** statistically designed experiments(DOES),along with linear and multiple linear regression ,after that comes the **scale up co-correlations** which translates the operating condition between different scales or pieces of equipments, all steps are culminated into **risk analysis** which determines the significance of effects and any combination of above .





8) CONTINUOUS IMPROVEMENT OF VARIOUS PROCESS AND THE PRODUCT

Various processes like manufacturing, performance, monitoring, market variance are made to acceptable changes by continuous improvement to increase the product lifecycle with regular feedbacks which is the basis of expanded knowledge and results in management with original concept intact.

9) Conclusion: Qbd is the developmental approach which should be adapted based on the complexity and specificity of product and design, FDA encourages these practices to be included in their application by the industry, using QBD does not bring about any change in the regional regulatory process but provides more of scientifically proven flexible approaches to them and for which in any case the adherence to GMP is any required. Various processes like inspections and reviews, and the flexible regulatory approaches to facilitate these does prove that, opportunity does exist to develop more appropriately factors depending on the level of understanding achieved and adapted quality system in place, the approved design space described within the manufacturing process movements without further regulatory views, with a reduction of post approval submissions, and a real time release testing leading to reduction of end product release testing.

References:

1. CON ICH Topic Q8 (R2), "ICH harmonised tripartite guideline," in *Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH '09)*, Pharmaceutical Development, 2009. View at: Google Scholar
2. A. B. Godfrey and R. S. Kenett, "Joseph M. Juran, a perspective on past contributions and future impact," *Quality and Reliability Engineering International*, vol. 23, no. 6, pp. 653–663, 2007. View at: Google Scholar
3. P. Nethercote, P. Borman, T. Bennett et al., *QbD for Better Method Validation & Transfer*, Pharmaceutical Manufacturing 2010.
4. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceutical-cal for Human Use, Topic Q8 (R2): Pharmaceutical Development, Geneva, (2009)
5. Vemuri Pavan Kumar N. Vishal Gupta, A Review on quality by design approach (QBD) for Pharmaceuticals, *International Journal of drug development and research*, Vol. 7, Issue 1 January March 2011
6. S. M. Khamanga and R. B. Walker, "The use of experimental design in the development of an HPLC-ECD method for the analysis of captopril," *Talanta*, vol. 83, no. 3, pp. 1037–1049, 2011. View at: Publisher Site | Google Scholar
7. E. M. Sheldon and J. B. Downar, "Development and validation of a single robust HPLC method for the characterization of a pharmaceutical starting material and impurities from three suppliers using three separate synthetic routes," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 23, no. 2-3, pp. 561–572, 2000. View at: Publisher Site | Google Scholar
8. P. F. Gavin and B. A. Olsen, "A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603)," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 46, no. 3, pp. 431–441, 2008. View at: Publisher Site | Google Scholar
9. ICH Topic Q2 (R1), "ICH harmonised tripartite guideline," in *Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH '94)*, Validation of Analytical Procedures, 1994. View at: Google Scholar
10. ICH Topic Q9, "ICH harmonised tripartite guideline," in *Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH '94)*, Quality Risk Management, 2005. View at: Google Scholar
11. P. Borman, P. Nethercote, M. Chatfield et al., *The Application of Quality by Design to Analytical Methods*, PharmTech, 2007.
12. L. X. Yu, "Pharmaceutical quality by design: product and process development, understanding, and control," *Pharmaceutical Research*, vol. 25, no. 4, pp. 781–791, 2008. View at: Publisher Site | Google Scholar
13. M. Pohl, M. Schweitzer, G. Hansen et al., "Implications and opportunities of applying the principles of QbD to analytical measurements," *Pharmaceutical Technology Europe*, vol. 22, no. 2, pp. 29–36, 2010. View at: Google Scholar
14. *The United States Pharmacopoeia 27, the National Formulary 22*, Asian Edition, United States Pharmacopoeial Convention, 2004.
15. Vikas PM, Satyanarayana DT, Kumar DV, Mounika E, Latha MS, Anusha R and Sathish Y: Development and validation of new RP-HPLC method for the determination of Sofosbuvir in pure form. *Wor J of Pharmacy and Pharmaceutical Sci* 2016.
16. International Conference on Harmonization (ICH) Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) (May 2011).
17. Schweitzer, M.; Pohl, M.; Hanna-Brown, M.; Nethercote, P.; Borman, P.; Hansen, G.; Smith, K.; Larew J. Implications and Opportunities of Applying QbD Principles to Analytical Measurements. *Pharm. Tech.* 2010, 34 (2) 52-59.
18. Vogt, F.G.; Kord A.S. Development of Quality-By-Design Analytical Methods. *J. Pharm. Sci.* 2011, 100(3), 797-812.
19. Bhatt, D.A.; Rane, S.I. QbD Approach to Analytical RP-HPLC Method Development and its Validation. *Int. J. Pharm*
20. P. Borman, P. Nethercote, M. Chatfield et al., *The Application of Quality by Design to Analytical Methods*, PharmTech, 2007.